Everpure, a corporate data storage provider, surged to record highs in early trading on Thursday. The move followed the company’s release of an updated, higher financial forecast. The revised guidance signaled stronger confidence in its near-term business outlook, prompting investors to buy.

After an FDA expert panel discussed Grail’s blood-based cancer screening test, trading in Grail shares was halted intraday on Wednesday. The test is designed to enable earlier cancer detection using a blood sample. Panel support is seen as a key step in the approval process.

U.S. fintech company SoFi said its stablecoin partnership with Mastercard has officially launched. The move marks SoFi’s expansion from consumer finance into the stablecoin space. The company’s shares rose following the announcement.

Viking Therapeutics and Roche reported positive weight-loss drug data early Tuesday. Viking shares jumped following the update. Shares of Eli Lilly and Novo Nordisk declined, underscoring shifting expectations about competition in the obesity-drug market.

Grail’s stock surged more than 30% on Monday after the U.S. Food and Drug Administration issued a positive briefing document ahead of a Wednesday meeting of its Oncology Drugs Advisory Committee. Investors increased bets that the company’s multi-cancer early detection blood test could win approval.

A U.S. federal judge has made public a detailed remedies framework in Google’s ad tech antitrust case, though the specific terms have not yet been disclosed. Alphabet shares edged higher on Thursday, as investors’ initial reaction to the potential remedy appeared muted.

Oscar Health has lowered its medical cost outlook, a move that lifted its shares. The company’s strategy of taking market share in a shrinking Affordable Care Act market is working for now. Analysts caution that the benefit may prove short-lived.

Axon said it plans to issue $1 billion of convertible notes to replenish its cash reserves and avoid high interest rates. The move also signals potential future equity dilution, which weighed on the stock on the day.

Definium Therapeutics said its synthetic LSD delivered positive results in easing anxiety symptoms, sending the stock sharply higher again after the announcement. The company’s shares are up 190% in 2026. The clinical trial success further lifted investor confidence.